Friday 16 October 2026 Export ALXO’s income statement to Excel — free account

ALX Oncology Holdings Inc.

In the quarter to June 2026, EPS grew 73.5%, free cash flow grew 31.7% and total debt fell 3.34%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.06 0.06 +6.00%

Follow ALXO

Alert me

Market cap: $138.3M
P/E: 0.0×
Fwd P/E: −8.6×
Dividend yield: —
F-score: n/a
Altman Z: 154.45
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 5.00

Total sells 0.04

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	1	—	—	—	—	—	—	—	—
Sell	—	—	1	1	2	—	—	—	1	2	—	—

Insider Ownership 28.01%

Capital & Financial Ratios $m

Market Cap 138.28

Revenue 2.44

Net Income (80.89)

Free Cash Flow (70.91)

Net Debt (128.52)

Current Ratio 9.71

Debt/Equity 0.07

P/E ratio 0.00

Fwd P/E (8.57)

P/S ratio 58.97

P/B ratio 1.06

Past 5Y EPS Growth —

This Y EPS Growth 70.56%

Next Y EPS Growth 2.21%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth 34.91%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 29.92%

10-year low 10-year high

P/B against its own 10 years 27.32%

10-year low 10-year high

EV/Sales against its own 10 years 6.49%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	183	128	45	138
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	189	134	51	143

	2023	2024	2025	Q'26
Payables	9	4	5	3
ST’ Debt	—	0	5	—
Other	—	—	—	—
	36	19	25	15

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(42.95%)	(53.80%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’20	1	1	—	0	1
’19	—	1	1	—	5

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	(16)	—	—	—
’25	(25)	(23)	(17)	(19)	(84)
’24	(38)	(27)	(25)	(32)	(122)
’23	(28)	(32)	(31)	(40)	(130)
’22	(21)	(17)	(31)	(21)	(89)
’21	(5)	(21)	(25)	(17)	(68)
’20	(9)	(6)	(10)	(14)	(38)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	(16)	—	—	—
’25	(25)	(23)	(17)	(19)	(84)
’24	(38)	(27)	(26)	(32)	(122)
’23	(29)	(33)	(30)	(40)	(132)
’22	(21)	(17)	(31)	(21)	(91)
’21	(5)	(21)	(25)	(22)	(73)
’20	(9)	(6)	(10)	(14)	(38)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.17)	(0.13)	—	—	—
’25	(0.58)	(0.49)	(0.41)	(0.42)	(1.90)
’24	(0.71)	(0.76)	(0.58)	(0.55)	(2.58)
’23	(0.74)	(0.84)	(1.24)	(0.93)	(3.74)
’22	(0.60)	(0.81)	(0.87)	(0.75)	(3.03)
’21	(0.35)	(0.40)	(0.61)	(0.70)	(2.07)
’20	(1.74)	(4.41)	(0.36)	(0.50)	(2.76)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	28.01	20.31	5.82	3.94	1.19	0.40	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	117.45	91.52	22.40	15.93	17.83	2.27
People
People	Employees	—	—	—	15	23	43	58	72	80	43
	Revenue/emp, $m	—	—	0.00	0.32	0.05	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	2	5	1	—	—	—	—	—
	Gross margin, %	—	—	9.05	9.09	9.05	0.00	0.00	—	—	—
	EBT	—	—	(14)	(19)	(45)	(83)	(123)	(161)	(135)	(102)
	EBT margin, %	—	—	(662.12)	(400.52)	(3,849.32)	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	(14)	(19)	(46)	(83)	(123)	(161)	(135)	(102)
	Depreciation	—	—	0	0	1	0	(1)	(5)	(4)	0
Per share, $
Per share, $	Revenue	—	—	0.75	1.56	0.06	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	(4.99)	(6.26)	(2.76)	(2.07)	(3.03)	(3.74)	(2.58)	(1.90)
	Cash flow	—	—	(4.79)	(4.63)	(2.07)	(1.69)	(2.19)	(3.03)	(2.34)	(1.57)
	Capex	—	—	(0.24)	(0.11)	0.00	(0.12)	(0.04)	(0.03)	(0.01)	0.00
	Free cash flow	—	—	(5.03)	(4.75)	(2.07)	(1.81)	(2.23)	(3.06)	(2.35)	(1.57)
	Book value	—	—	0.00	(22.96)	23.25	9.01	6.47	4.41	2.18	0.48
	Shares, m	—	—	3	3	18	40	41	43	52	54
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	—	—	—	—	—
	P/S	—	—	25.44	25.44	653.57	—	—	—	—	—
	P/B	—	—	0.00	0.00	3.71	—	—	—	—	—
	EV/Sales	—	—	0.67	0.67	477.83	—	—	—	—	—
	EV/FCF	—	—	(0.12)	(0.12)	(30.40)	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	(13)	(14)	(38)	(68)	(89)	(130)	(122)	(84)
	Capex	—	—	(1)	0	0	(5)	(1)	(1)	0	0
	Free cash flow	—	—	(14)	(15)	(38)	(73)	(91)	(132)	(122)	(84)
Balance, $m
Balance, $m	Working capital	—	—	8	5	430	352	243	153	116	26
	Total debt	—	—	—	5	—	3	10	10	10	10
	Net debt	—	—	(8)	(4)	(434)	(361)	(256)	(173)	(118)	(35)
	Shareholders’ equity	—	—	—	(71)	430	363	263	190	114	26
Returns, %
Returns, %	ROA	—	—	0.00	(435.95)	(22.81)	(20.45)	(35.97)	(58.58)	(69.10)	(98.34)
	ROIC	—	—	0.00	0.00	0.00	(2,661.67)	(1,036.13)	(640.53)	0.00	0.00
	ROE	—	—	28.43	38.02	(28.36)	(21.05)	(39.42)	(70.97)	(88.91)	(145.70)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2020 · latest quarter Dec 2020

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MSLE Satellos Bioscience Inc.	$145.1M	— (loss-making)	—	—	n/m	−65.66% (below 0%: shrinking)	99.26%	0.00%	Compare
MOLN Molecular Partners AG Sponsored ADR	$143.5M	— (loss-making)	— (loss-making)	−98.86% (below 0%: shrinking)	n/m	+23.77% (above 0%: growing)	0.00%	0.00%	Compare
ALXO ALX Oncology Holdings Inc.	$138.3M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	+31.65% (above 0%: growing)	0.00%	0.00%
AVXL Anavex Life Sciences Corp.	$137.2M	— (loss-making)	—	—	n/m	+27.02% (above 0%: growing)	—	0.00%	Compare
KRRO Korro Bio, Inc.	$137.1M	— (loss-making)	— (loss-making)	−86.28% (below 0%: shrinking)	n/m	+12.07% (above 0%: growing)	100.00%	0.00%	Compare
ANTX AN2 Therapeutics, Inc.	$135.9M	— (loss-making)	—	—	n/m	+7.91% (above 0%: growing)	0.00%	0.00%	Compare
CUE Cue Biopharma, Inc.	$135.6M	— (loss-making)	— (loss-making)	+166.66% (above 0%: growing)	n/m	−742.65% (below 0%: shrinking)	100.00%	(1,113.30%)	Compare
TLSA Tiziana Life Sciences Ltd	$134.7M	— (loss-making)	—	—	−258.11% (below 0%: shrinking)	+18.03% (above 0%: growing)	0.00%	—	Compare
ABOS Acumen Pharmaceuticals, Inc.	$120.8M	— (loss-making)	—	—	n/m	+43.23% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$136.5M	—	—	−86.28%	—	+15.05%	0.00%	0.00%

All 614 Biotechnology stocks →

ALX Oncology Holdings Inc. (ALXO) key facts

ALX Oncology Holdings Inc. (ALXO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ALXO traded at $1.06, a market capitalization of $138.3 million.
Return on equity was −145.7% and debt-to-equity 0.07.

Source: company filings (standardised) and stockrow calculations.